Our Medicines

Senseion Therapeutics’ SN-40X Addresses an Unmet Clinical Need

Metabolic disease is a global pandemic. Current therapies do not adequately control metabolic disease or its cardiovascular complications.

Perfectly Poised to Enter the Global Metabolic Disease Market

Senseion is using new tools to develop and advance its first-in-class drug candidate SN-40X for the treatment of diabetes and its complications, including cardiovascular disease.

THERAPEUTIC PROMISE

Modulating chloride ion-channel activity across multiple tissues will improve systemic metabolism and provide a new approach for treating metabolic syndrome.

Senseion Therapeutics was formed to translate foundational discoveries and Intellectual Property (IP) from the Sah lab into therapeutics for chloride ion-channel diseases.